Literature DB >> 21161615

Alterations of the B-cell response by HIV-1 replication.

Xiaoying Shen1, Georgia D Tomaras.   

Abstract

While the hallmark of HIV-1 infection is the progressive depletion of CD4(+) T cells, extensive B-cell dysfunction ensues that impairs the quality of the humoral response. HIV-1 infection causes hypergammaglobulinemia, polyclonal activation, loss of memory B-cell subsets, B-cell exhaustion, aberrant B-cell surface markers, and impaired humoral responses against infections and vaccinations. The totality of the mechanisms that contribute to B-cell dysfunction in vivo is unknown, although roles for HIV proteins (Env, Tat, and Nef) and virions binding to CD21 on B cells have been identified. Recent studies suggest that early antiretroviral therapy, that minimizes virus replication, can profoundly preserve the early B-cell response to HIV-1. Thus, it is clear that there is an intricate interplay between HIV replication and stimulation of the host B-cell response to infection. A better understanding of how HIV-1 subverts a productive B-cell response is needed to inform vaccine strategies that aim to elicit long-lived plasma cells and memory B-cell responses that can act quickly upon antigen stimulation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21161615      PMCID: PMC3638746          DOI: 10.1007/s11904-010-0064-2

Source DB:  PubMed          Journal:  Curr HIV/AIDS Rep        ISSN: 1548-3568            Impact factor:   5.071


  50 in total

1.  Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1.

Authors:  Marie Pancera; Jason S McLellan; Xueling Wu; Jiang Zhu; Anita Changela; Stephen D Schmidt; Yongping Yang; Tongqing Zhou; Sanjay Phogat; John R Mascola; Peter D Kwong
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  Pseudovirion particles bearing native HIV envelope trimers facilitate a novel method for generating human neutralizing monoclonal antibodies against HIV.

Authors:  Mark D Hicar; Xuemin Chen; Bryan Briney; Jason Hammonds; Jaang-Jiun Wang; Spyros Kalams; Paul W Spearman; James E Crowe
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

3.  Therapeutic antibodies, vaccines and antibodyomes.

Authors:  Dimiter S Dimitrov
Journal:  MAbs       Date:  2010-05-14       Impact factor: 5.857

4.  Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus–infected patients before and after antiretroviral therapy.

Authors:  Yolande Richard; Corinne Amiel; Vincent Jeantils; Denis Mestivier; Alain Portier; Guy Dhello; Jean Feuillard; Rita Creidy; Jean-Claude Nicolas; Martine Raphael
Journal:  J Infect Dis       Date:  2010-11-01       Impact factor: 5.226

5.  Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1.

Authors:  Xueling Wu; Zhi-Yong Yang; Yuxing Li; Carl-Magnus Hogerkorp; William R Schief; Michael S Seaman; Tongqing Zhou; Stephen D Schmidt; Lan Wu; Ling Xu; Nancy S Longo; Krisha McKee; Sijy O'Dell; Mark K Louder; Diane L Wycuff; Yu Feng; Martha Nason; Nicole Doria-Rose; Mark Connors; Peter D Kwong; Mario Roederer; Richard T Wyatt; Gary J Nabel; John R Mascola
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

6.  Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01.

Authors:  Tongqing Zhou; Ivelin Georgiev; Xueling Wu; Zhi-Yong Yang; Kaifan Dai; Andrés Finzi; Young Do Kwon; Johannes F Scheid; Wei Shi; Ling Xu; Yongping Yang; Jiang Zhu; Michel C Nussenzweig; Joseph Sodroski; Lawrence Shapiro; Gary J Nabel; John R Mascola; Peter D Kwong
Journal:  Science       Date:  2010-07-08       Impact factor: 47.728

Review 7.  Macrophage signaling in HIV-1 infection.

Authors:  Georges Herbein; Gabriel Gras; Kashif Aziz Khan; Wasim Abbas
Journal:  Retrovirology       Date:  2010-04-09       Impact factor: 4.602

8.  Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques.

Authors:  Cherie T Ng; J Pablo Jaworski; Pushpa Jayaraman; William F Sutton; Patrick Delio; LaRene Kuller; David Anderson; Gary Landucci; Barbra A Richardson; Dennis R Burton; Donald N Forthal; Nancy L Haigwood
Journal:  Nat Med       Date:  2010-10-03       Impact factor: 53.440

Review 9.  Induction of immunity to human immunodeficiency virus type-1 by vaccination.

Authors:  M Juliana McElrath; Barton F Haynes
Journal:  Immunity       Date:  2010-10-29       Impact factor: 31.745

10.  Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates.

Authors:  Christopher Sundling; Mattias N E Forsell; Sijy O'Dell; Yu Feng; Bimal Chakrabarti; Srinivas S Rao; Karin Loré; John R Mascola; Richard T Wyatt; Iyadh Douagi; Gunilla B Karlsson Hedestam
Journal:  J Exp Med       Date:  2010-08-02       Impact factor: 14.307

View more
  17 in total

Review 1.  Post-Treatment Controllers: Role in HIV "Cure" Research.

Authors:  Leslie R Cockerham; Hiroyu Hatano; Steven G Deeks
Journal:  Curr HIV/AIDS Rep       Date:  2016-02       Impact factor: 5.071

2.  HIV Tat induces a prolonged MYC relocalization next to IGH in circulating B-cells.

Authors:  D Germini; T Tsfasman; M Klibi; R El-Amine; A Pichugin; O V Iarovaia; C Bilhou-Nabera; F Subra; Y Bou Saada; A Sukhanova; D Boutboul; M Raphaël; J Wiels; S V Razin; S Bury-Moné; E Oksenhendler; M Lipinski; Y S Vassetzky
Journal:  Leukemia       Date:  2017-03-31       Impact factor: 11.528

3.  Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques.

Authors:  Thorsten Demberg; Egidio Brocca-Cofano; Peng Xiao; David Venzon; Diego Vargas-Inchaustegui; Eun Mi Lee; Irene Kalisz; V S Kalyanaraman; Janet Dipasquale; Katherine McKinnon; Marjorie Robert-Guroff
Journal:  J Virol       Date:  2012-09-12       Impact factor: 5.103

Review 4.  HIV-associated immune complex kidney disease.

Authors:  Ehsan Nobakht; Scott D Cohen; Avi Z Rosenberg; Paul L Kimmel
Journal:  Nat Rev Nephrol       Date:  2016-01-19       Impact factor: 28.314

5.  Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.

Authors:  Livio Azzoni; Andrea S Foulkes; Cynthia Firnhaber; Xiangfan Yin; Zhi Q Xiang; Yan Li; Wendy Stevens; Robert Gross; Hildegund C J Ertl; Ian Sanne; Luis J Montaner
Journal:  AIDS       Date:  2012-07-17       Impact factor: 4.177

6.  Associations of Viral Seroreactivity with AIDS-Related Non-Hodgkin Lymphoma.

Authors:  Minkyo Song; Bryan A Bassig; Noemi Bender; James J Goedert; Cheryl A Winkler; Nicole Brenner; Tim Waterboer; Charles S Rabkin
Journal:  AIDS Res Hum Retroviruses       Date:  2020-03-02       Impact factor: 2.205

7.  Acquired hypogammaglobulinemia and pathogen-specific antibody depletion after solid organ transplantation in human immunodeficiency virus infection: A brief report.

Authors:  Margaret Newman; Kevin Gregg; Randee Estes; Kenneth Pursell; David Pitrak
Journal:  Transpl Infect Dis       Date:  2019-10-14       Impact factor: 2.228

8.  B cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.

Authors:  Peter Oballah; Britta Flach; Leigh A Eller; Michael A Eller; Benson Ouma; Mark de Souza; Hannah N Kibuuka; Fred Wabwire-Mangen; Bruce K Brown; Nelson L Michael; Merlin L Robb; David Montefiori; Victoria R Polonis
Journal:  PLoS One       Date:  2011-08-23       Impact factor: 3.240

9.  The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults.

Authors:  Thomas G Johannesson; Ole S Søgaard; Martin Tolstrup; Mikkel S Petersen; Jens M Bernth-Jensen; Lars Østergaard; Christian Erikstrup
Journal:  PLoS One       Date:  2012-07-30       Impact factor: 3.240

10.  Increased IgG but normal IgA anti-pneumococcal protein antibodies in lung of HIV-infected adults.

Authors:  Andrea M Collins; Sherouk El Batrawy; Stephen B Gordon; Daniela M Ferreira
Journal:  Vaccine       Date:  2013-05-10       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.